AstraZeneca ' s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows

AstraZeneca Plc AZN released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC). The data showed that Imfinzi plus standard-of-care chemotherapy demonstrated a clinically…#astrazenecaplcazn #topaz1phase3 #imfinzi #topaz1 #median #azn
Source: Reuters: Health - Category: Consumer Health News Source Type: news